Patient-Reported Outcomes Among Patients Ages Two to Seventeen Years With Polyarticular-Course Juvenile Idiopathic Arthritis Treated With Subcutaneous Abatacept: Two-Year Results From an International Phase III Study.

Nicolino Ruperto Daniel J LovellAlberto BermanFrancisco Ávila-ZapataGerd HorneffMaria AlessioMara L BeckerAlexandre BelotRuben Burgos-VargasMaria L GamirClaudia Goldenstein-SchainbergIloite M ScheibelMaria T TerreriLawrence ZemelJoe ZhuoMargarita AskelsonRobert WongAlberto MartiniHermine I Brunnernull null

Published in: Arthritis care & research (2022)

Early and sustained PRO improvements were reported in this phase III, open-label trial of subcutaneous abatacept in patients with pJIA.

Keyphrases

phase iii
juvenile idiopathic arthritis
open label
patient reported outcomes
rheumatoid arthritis
clinical trial
phase ii
disease activity
rheumatoid arthritis patients
phase ii study
double blind
placebo controlled
study protocol
systemic lupus erythematosus
randomized controlled trial
anti inflammatory